| Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England Journal of Medicine 379 (22), 2108-2121, 2018 | 3742 | 2018 |
| Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, ... New England Journal of Medicine 366 (6), 520-529, 2012 | 3390 | 2012 |
| Palbociclib and letrozole in advanced breast cancer RS Finn, M Martin, HS Rugo, S Jones, SA Im, K Gelmon, N Harbeck, ... New England journal of medicine 375 (20), 1925-1936, 2016 | 2550 | 2016 |
| Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ... New England Journal of Medicine 380 (20), 1929-1940, 2019 | 1988 | 2019 |
| Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy DG DeNardo, DJ Brennan, E Rexhepaj, B Ruffell, SL Shiao, SF Madden, ... Cancer discovery 1 (1), 54-67, 2011 | 1871 | 2011 |
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation JK Litton, HS Rugo, J Ettl, SA Hurvitz, A Gonçalves, KH Lee, ... New England Journal of Medicine 379 (8), 753-763, 2018 | 1799 | 2018 |
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer KD Miller, LI Chap, FA Holmes, MA Cobleigh, PK Marcom, ... Journal of clinical oncology 23 (4), 792-799, 2005 | 1719 | 2005 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1224 | 2018 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1208 | 2020 |
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer KL Blackwell, HJ Burstein, AM Storniolo, H Rugo, G Sledge, M Koehler, ... Journal of clinical oncology 28 (7), 1124-1130, 2010 | 1164 | 2010 |
| Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo … PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ... The Lancet 390 (10105), 1833-1842, 2017 | 1158 | 2017 |
| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1124 | 2022 |
| Breast cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual AE Giuliano, JL Connolly, SB Edge, EA Mittendorf, HS Rugo, LJ Solin, ... CA: a cancer journal for clinicians 67 (4), 290-303, 2017 | 1035 | 2017 |
| Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results … P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ... The Lancet Oncology 21 (1), 44-59, 2020 | 1025 | 2020 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1020 | 2020 |
| Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells B Ruffell, D Chang-Strachan, V Chan, A Rosenbusch, CMT Ho, N Pryer, ... Cancer cell 26 (5), 623-637, 2014 | 957 | 2014 |
| 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... The Breast 31, 244-259, 2017 | 874 | 2017 |
| ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F Andre, CH Barrios, ... The Breast 23 (5), 489-502, 2014 | 836 | 2014 |
| Cancer-related fatigue, version 2.2015 AM Berger, K Mooney, A Alvarez-Perez, WS Breitbart, KM Carpenter, ... Journal of the National Comprehensive Cancer Network 13 (8), 1012-1039, 2015 | 832 | 2015 |
| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 828 | 2021 |
